Sự kết hợp giữa bevacizumab và bức xạ trong ung thư biểu mô uveal: một nghiên cứu tiền lâm sàng in vitro và in vivo

Gragoudas ES, Goietin M, Verhey L, Munzenreider J, Suit HD, Koehler A (1980) Proton beam irradiation. An alternative to enucleation for intraocular melanomas. Ophtalmology 87:571–581 Desjardins L, Levy C, d’Hermies F, Frau E, Schlienger P, Habrand JL, Mammar H, Schwartz L, Mazal A, Delacroix S, Nauraye C, Ferrand R, Asselain B (1997) Résultats préliminaires de la protonthérapie du mélanome de la choroïde au centre de protonthérapie d’Orsay (CPO): les 464 premiers cas. Cancer Radiother 1:222–226 Courdi A, Caujolle JP, Grange JD, Diallo-Rosier L, Sahel J, Bacin F, Zur C, Gastaud P, Iborra-Brassart N, Hérault J, Chauvel P (1999) Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys 45:5–11 Char DH, Quivey JM, Castro JR, Kroll PT (1993) Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophtalmology 100:1547–1554 Egan KM, Gragoudas ES, Seddon JM, Glynn RJ, Munzenreider JE, Goitein M, Verhey L, Urie M, Koehler A (1989) The risk of enucleation after proton beam irradiation of uveal melanoma. Ophtalmology 96:1377–1382 Egan KM, Ryan LM, Gragoudas ES (1998) Survival implications of enucleation after definitive radiotherapy for choroïdal melanoma: an example of regression on time-dependent covariates. Arch Ophthalmol 116:366–370 Sheidow TG, Hooper PL, Crukley C, Young J, Heathcote JG (2000) Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophtalmol 84:750–756 Boyd SR, Tan D, Bunce C, Gittos A, Neale MH, Hungerford JL, Charnock-Jones S, Cree IA (2002) Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophtalmol 86:448–452 Missotten GS, Notting IC, Schlingemann RO, Zijlmans HJ, Lau C, Eilers PH, Keunen JE, Jager MJ (2006) Vascular endothelial growth factor in eyes with uveal melanoma. Arch Ophtalmol 124:1428–1434 Rosenblatt MI, Azar DT (2006) Antiangiogenic therapy: prospects for treatment of ocular tumors. Semin Ophthalmol 21:151–160 Triozzi PL, Eng C, Singh AD (2008) Targeted therapy for uveal melanoma. Cancer Treat Rev 34:247–258 Spagnolo F, Caltabiano G, Queirolo P (2012) Uveal melanoma. Cancer Treat Rev (in press) O’Reilly M (2006) Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 16:45–50 Kan-Mitchell J, Mitchell MS, Rao N, Ligett PE (1989) Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci 30:829–834 Carmichael J, De Graff W, Gazdar AF, Mumma JO, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensibility testing. Cancer Res 47:936–940 Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495–511 Guérin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM, Milano G (2008) Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 134:51–57 Avila MP, Farah ME, Santos A, Duprat JP, Woodward BW, Nau J (2009) Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 93:305–309 el Filali M, van der Velden PA, Luyten GP, Jager MJ (2012) Anti-angiogenic therapy in uveal melanoma. Dev Ophthalmol 49:117–136 Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP (2005) Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835–842 Nieder C, Wiedenmann N, Andraschke M, Molls N (2006) Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 32:348–364 Finger PT (2008) Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 70:974–977 Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989 Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13:3395–3402 Yang H, Jager MJ, Grossniklaus HE (2010) Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 51:2835–2842 Lefèvre G, Babchia N, Calipel A, Mouriaux F, Faussat AM, Mrzyk S, Mascarelli F (2009) Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest Ophthalmol Vis Sci 50:1047–1057 Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135:807–810 Adams KS, Abramson DH, Ellsworth RM, Haik BG, Bedford M, Packer S, Seddon J, Albert D, Polivogianis L (1988) Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rates. Br J Ophthalmol 72:494–497 Depotter P, Shields CL, Shields JA, Cater JR, Tardio DJ (1994) Impact of enucleation versus plaque radiotherapy in the management of juxtapapillary choroidal melanoma on patient survival. Br J Ophthalmol 78:109–114 Augsburger JJ, Schneider S, Freire J, Brady LW (1999) Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroïdal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol 237:555–559